Niva Bupa Health Insurance Company Limited provides health insurance products covering individuals, families and groups across India. Its business benefits from increasing health-insurance penetration and rising healthcare expenditure. Product innovation, digital distribution and expansion into underserved markets can support growth. Claims costs, medical inflation, persistency, distribution expenses, regulatory changes and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Beta |
|---|---|---|---|---|---|---|---|
| ₹14,109 cr | — | — | 38.5 | 1.97 | 3.68 | 9.5% | 0.28 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Mar 2026 | 2,302 | 345 | 1.87 | +65.5% | +37.6% | 15.0% |
| Dec 2025 | 1,767 | -88 | -0.47 | -771.4% | +53.3% | -5.0% |
| Sep 2025 | 1,450 | -35 | -0.19 | -337.5% | +4.1% | -2.4% |
| Jun 2025 | 1,288 | -91 | -0.50 | — | — | -7.1% |
| Mar 2025 | 1,672 | 206 | 1.13 | — | — | 12.3% |
| Dec 2024 | 1,152 | 13 | 0.07 | — | — | 1.1% |
| Sep 2024 | 1,393 | 13 | 0.08 | — | — | 0.9% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✗ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✗ 50-day above the 150- and 200-day ✗ Close above the 50-day ✗ At least 25% above the 52-week low · low 68.40 ✓ Within 25% of the 52-week high · high 88.36 ✗ RS percentile 70 or more · RS 42 Trend template - the gate, measured: a modest 21-day edge. | 3/8 | 3 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 1 - basing | |
| CAN SLIM | ✓ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 88.36 ✓ S more volume on up days than down days (50 sessions) · 1.06x ✗ L RS percentile 80 or more · RS 42 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 4/5 | Strong |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 91.40 ✓ Box bottom confirmed (3 sessions holding) · bottom 71.98 ✗ Close above the box top · close 76.28 ✗ Volume at least 1.5x its 50-day average · 0.4x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 49/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 91.40 ✗ Close above the prior 20-session high · 83.50 ✗ Close below the prior 20-session low · 71.98 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Graham | ✗ Price at or below the Graham number · Graham number 30.31 ✗ P/E 15 or less · P/E 38.7 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 3.68 — Current ratio 2 or more — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 40/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NIVABUPA this stock | -4.2 | -11.4 | -1.7 | +0.5 | — | — | 38.5 | 3.68 | 9.5 | — | — | — | — | 14,109 | — | — | 2.0 | 0.28 |
| SAKAR | -21.8 | +2.7 | +51.5 | +162.7 | +158.4 | +464.3 | 57.0 | 6.33 | 10.0 | 12.9 | — | 0.17 | 30.8 | 2,054 | 272 | 36 | 16.2 | 0.69 |
| KOVAI | -5.6 | -0.9 | +7.0 | +128.0 | +118.8 | +256.0 | 25.5 | 4.87 | 19.4 | — | — | — | — | 6,429 | — | — | 234.2 | — |
| AHCL | +17.8 | +79.8 | +86.2 | +112.4 | — | — | 11.1 | 6.23 | 47.4 | — | — | 0.19 | 30.7 | 1,434 | — | — | 2.4 | 0.44 |
| VIJAYA | -12.2 | +2.5 | +33.7 | +37.9 | +134.0 | +143.8 | 75.1 | 14.71 | 19.7 | 30.3 | — | 0.00 | 39.6 | 14,078 | 857 | 188 | 18.2 | 0.54 |
| ENTERO | -13.2 | +26.4 | +18.2 | +35.9 | — | — | 52.2 | 3.88 | 6.7 | 10.7 | — | 0.34 | 26.4 | 6,545 | 7,128 | 168 | 28.8 | 0.36 |
| AMANTA | -13.3 | -0.0 | +21.9 | +34.8 | — | — | 39.6 | 2.57 | — | — | — | 1.06 | — | — | 291 | 15 | 4.2 | 0.73 |
| YATHARTH | -14.8 | +14.4 | +30.6 | +19.8 | +147.7 | — | 51.6 | 5.18 | 10.0 | 12.4 | — | 0.14 | 30.2 | 9,356 | 1,334 | 174 | 18.8 | 0.88 |
| LALPATHLAB | -2.8 | +8.9 | +30.0 | +18.6 | +47.0 | -0.3 | 56.8 | 12.32 | 21.6 | 29.1 | — | 0.00 | 36.2 | 30,900 | 2,891 | 546 | 32.5 | 0.41 |
| THYROCARE | -15.3 | -15.2 | +19.9 | +13.6 | +151.4 | +22.7 | 42.6 | 12.80 | 28.8 | 37.8 | — | 0.00 | 28.2 | 7,497 | 876 | 176 | 11.1 | 0.47 |
| STARHEALTH | -0.9 | -6.7 | +7.0 | +7.6 | -8.9 | — | 35.7 | 3.15 | 8.9 | — | — | — | — | 31,904 | — | — | 15.3 | 0.41 |